Schonfeld Strategic Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-822,100	Closed	-$14.6M	–	1319
2018 Q3	$14.6M	Buy	822,100 +681,900	+486%	+$11.7M	0.65%	20
2018 Q2	$1.94M	Sell	140,200 -245,315	-64%	-$2.91M	0.1%	272
2018 Q1	$3.5M	Buy	+385,515	New	+$2.13M	0.26%	110

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Schonfeld Strategic Advisors's ECYT Position: Q4 2018 in Review

Schonfeld Strategic Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 822,100 shares — an estimated $14.6M sold.

Schonfeld Strategic Advisors first reported a position in ECYT in Q1 2018 and held it in 3 quarters. The position peaked at $14.6M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Schonfeld Strategic Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Schonfeld Strategic Advisors sold 822,100 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $14.6M.
Schonfeld Strategic Advisors first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Schonfeld Strategic Advisors's Endocyte, Inc. Common Stock position peaked at $14.6M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.